CoChat

Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors

Aksnes, T A, Reims, H M, Guptha, S, Moan, A, Os, I, Kjeldsen, S E · 2006 · Journal of Human Hypertension

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

We aimed to compare the effects of two different vasodilating principles, angiotensin II-receptor blockade and calcium channel blockade, on peripheral insulin-mediated glucose uptake in patients with hypertension and other cardiovascular risk factors. Twenty-one hypertensive patients (11 women and 10 men) with mean age 58.6 years (range 46-75 years), body mass index 29.2 +/- 1.0 kg/m(2) and blood pressure 160 +/- 3/96 +/- 2 mm Hg entered a 4-week run-in period with open-label amlodipine 5 mg. Thereafter they were randomized double-blindly to additional treatment with amlodipine 5 mg or losartan 100 mg. After 8 weeks of treatment, all patients underwent clinical examination and laboratory testing, and 17 of them underwent a hyperinsulinaemic isoglycaemic glucose clamp. After a 4-week open-label wash-out phase, the participants crossed over to the opposite treatment regimen and final examinations with hyperinsulinaemic isoglycaemic glucose clamp after another 8 weeks. Blood pressure was lowered to the same level in both treatment periods. The glucose disposal rate was significantly higher after treatment with losartan 100 mg + amlodipine 5 mg compared to amlodipine 10 mg (4.9 +/- 0.4 vs 4.2 +/- 0.5 mg/kg/min, P = 0.039). Thus our data suggest that angiotensin II-receptor blockade with losartan improves glucose metabolism at the cellular level beyond what can be expected by the vasodilatation and blood pressure reduction alone.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.jhh.1002087

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 26 references

Cited by

See all 31

Metadata

Authors
Aksnes, T. A., Reims, H. M., Guptha, S., Moan, A., Os, I., & Kjeldsen, S. E.
Affiliations
  • Oslo University Hospital (NO)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • MSD (Norway) (NO)
Corresponding author
Aksnes, T A
Venue
Journal of Human Hypertension
Published
2006-09-21
Volume
20
Issue
11
Pages
860-866
ISSN
  • 0950-9240 (ISSN-L)
  • 1476-5527
OpenAlex
W2046837981
Cited by
31
References
26
Citations by year
2023: 1 · 2022: 2 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 3 · 2013: 3 · 2012: 2
FWCI
2.13
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Human Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
losartan, angiotensin II receptor blockade, amlodipine, calcium channel blockers, insulin sensitivity, insulin-stimulated glucose uptake, glucose disposal rate, hypertension, cardiovascular risk factors, combination antihypertensive therapy
MeSH terms
Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Calcium Channel Blockers, Cardiovascular Diseases, Double-Blind Method, Female, Heart Rate, Humans, Hypertension, Insulin, Insulin Resistance, Lipids, Male, Middle Aged, Risk Factors, Uric Acid, Vasodilation, Glucose Clamp Technique, Biomarkers, Treatment Outcome, Amlodipine, Cross-Over Studies, Losartan, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. https://app.cochat.ai/papers/10.1038/sj.jhh.1002087
The paper
Aksnes, T. A., Reims, H. M., Guptha, S., Moan, A., Os, I., & Kjeldsen, S. E. (2006). Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. Journal of Human Hypertension. https://doi.org/10.1038/sj.jhh.1002087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.